Lucid Diagnostics Inc (LUCD) Stock Price, Quote & News

Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths th...

Industry: Medical Devices

Sector: Healthcare

Phone: 917 813 1828

Website: www.luciddx.com

Address:

360 Madison Avenue, 25th Floor, New York, United States

xx007xx Oct. 27 at 9:29 PM

$LUCD years of psychotic behavior…not healthy…

0 · Reply

PortfolioMgmt23 Oct. 27 at 7:05 PM

$LUCD @dmc4321 is posting a TON OF NEGATIVITIY. I can't ask for a better sign that GOOD NEWS is just ahead!

0 · Reply

dmc4321 Oct. 27 at 3:28 PM

$LUCD Last part got cut off.

1 · Reply

dmc4321 Oct. 27 at 3:09 PM

$LUCD People think that Companies buy Companies, They do NOT. People buy Companies. A single person or a very small group of people make the decision to buy a Company and for how much. They know there own future is at RISK. Their Competitors within the company want them to fail and will highlight if "Joe Bloggs OVERPAID" or made an "UNNECESSARY acquisition". If that is seen as true that individual or small group's future wealth and promotions will be VERY NEGATIVELY affected. They will not be trusted with potential deals of the same size and DEFINITELY not deals that are more strategic. So the fact that Lishan and Dennis have FAILED to launch ALL 5 products they have attempted MATTERS. That they have no Sales and Marketing TALENT MATTERS That $LUCD is broke in the Summer of 2026 MATTERS. That LUCD only managed to sell 1,000 EsoGuard tests to "CMS Covered Patients" in the first 6 MONTHS of 2025 (DESPITE having nearly 30 Sales People for OVER 5 years) REALLY MATTERS

0 · Reply

tds_ Oct. 27 at 1:13 PM

$LUCD NVS dropping $12 billion for RNA. A lot of big pharma money sloshing around out there....

1 · Reply

Ironbow Oct. 26 at 8:11 PM

$LUCD Dave…: Drink a beer, watch some football 🏈 …..You’re going to have a stroke //~

0 · Reply

dmc4321 Oct. 25 at 1:30 PM

$LUCD @oaksapollo Oaksapollo is lying again but his basic math is also sketchy. I cant be bothered to pick apart the MULTIPLE lies but will let you see how EVEN the BASIC Math is wrong. He said "A 36% growth rate would put Esoguard test volume at about 19,000 Q4 2026, close to $37M in revenue. Fully diluted with a revenue multiple of 6 (mean for biotech) you get a share price of around $4." Fully diluted TODAY there are 230 Million shares outstanding and LUCD is BROKE Summer 2026 so ANOTHER raise is "IMMINENT" 🤩 But we will ignore that! So 19,000 EsoGuard tests inQ4 2026 times $1983 per EsoGuard tests is actually close to $38 Million in Revenue Multiplied by Revenue Multiple of 6 is 😜 228,000,000 BUT we must DIVIDE by the FULLY DILUTED SHARE COUNT of 230,000,000 (its a little more!!😱😱😱) to gives us a share price of 99 CENTS 😱😱😱. 99 CENTS 😱😱😱. 99 CENTS 😱😱😱. 99 CENTS 😱😱😱. 99 CENTS 😱😱😱. 99 CENTS

2 · Reply

oaksapollo Oct. 25 at 5:31 AM

$LUCD What do you guys think is a reasonable number for average Q/Q test volume growth next year? Here are Cologuard numbers the first 2 years after launch: Q1 2015: 11K Q2: 21K Q3: 34K Q4: 38K Q1 2016: 40K Q2: 50K Q3: 68K Q4: 82K If you average the Q/Q growth rates, you get 36%. Keep in mind Cologuard got Medicare coverage in late 2014. A 36% growth rate would put Esoguard test volume at about 19,000 Q4 2026, close to $37M in revenue. Fully diluted with a revenue multiple of 6 (mean for biotech) you get a share price of around $4. Now consider: -Exact's revenue multiple in 2015 was over 20. -Uptake of Esoguard could be much faster than Cologuard because GI practices are already embracing it, whereas GIs fought Cologuard initially. If I plug in 45% Q/Q growth on average and a rev multiple of 10 (still half of Exact's in 2015), now the share price is $9 end of next year. Say growth is 60%, rev multiple 15, now it's $22. Any thoughts on how fast they can grow test vol?

2 · Reply

mlwtwits Oct. 24 at 9:26 PM

$LUCD 💲✅💲

0 · Reply

DonWanSan Oct. 24 at 9:25 PM

$LUCD any price predictions on this?

2 · Reply

Market Cap	170.85M
Revenue (ttm)	4.35M
Net Income (ttm)	-45.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,046.67%
Debt to Equity Ratio	3.22

Volume	636,600
Avg Vol	1,343,450
Day's Range	N/A - N/A
Shares Out	133.48M
Stochastic %K	76%
Beta	1.19
Analysts	Strong Sell
Price Target	$3.75